Jim Walsh has 25 years general management experience in the Healthcare industry with particular experience in Diagnostics. He is a Director of Trinity Biotech Plc, (NASDAQ: TRIB) an Irish Diagnostics company and is Executive Chairman of Biosensia Ltd. an Irish Point of Care Diagnostics Company.
Previously Dr. Walsh was Executive Chairman of GenCell Biosystems Ltd, a Genomics platform company, acquired by Becton Dickenson in October 2014. Until 2010 Dr. Walsh was CEO of Stokes Bio Ltd. a company specialising in the area of Molecular Diagnostics, acquired by Life Technologies. Prior to that Dr. Walsh was Non Executive Director of PuriCore Plc. (LSE : PURI), Dr. Walsh is also an investor in and a Director of a number of early stage Life-science Companies.
Elaine has over 10 years’ experience in R&D. Preiovioulsy a research fellow, Elaine has served as Principal Investigator, Co-investigator, and Key Personnel to lead the development of highly sensitive assays for molecular disease biomarkers using cost effective, highly portable, electrochemical detection which she is author on a multitude of high impact publications. She has successfully competed for research & SME grant funding of over €3.8m.
Elaine holds a BSc in Analytical Sciences and PhD in Physical Inorganic Chemistry from Dublin City University (DCU).
Kellie has over 10 years’ experience in R&D. Previously a research fellow, she has profound expertise in the area of biomaterials and cell sensing via selective and sensitive cell capture through clever innovations in the structure of the capture surface of which she is author on multiple high impact publications. She has successfully competed for research & SME grant funding of over €2.9m.
Kellie holds a BSc in Analytical Chemistry from Dublin City University and PhD in Diagnostics & Therapeutics from the Royal College of Surgeons in Ireland (RCSI).
Hazel is a highly skilled analytical chemist with extensive experience in electrochemistry, microfluidics, nucleic acid, pathogen, and patient sample handling and detection.
Her research has focused on creating modified interfaces for sensing and biomedical applications based on electrochemical sensing.
Hazel holds a BSc in Chemical & Pharmaceutical Sciences and PhD in Analytical Chemistry from Dublin City University (DCU).
Professor of Anaesthesia & Critical Care at Royal College of Surgeons in Ireland. Consultant in Anaesthesia and Intensive Care Medicine.
Sepsis lead in the RCSI Network of hospitals, reporting to the Lead in Critical Care Programs at the HSE.
Keith’s career, for more than 20 years, has been focussed on the development and commercialisation of innovative healthcare products and services.
Prior to Novus Diagnostics, Keith was responsible for global innovation alliances for Abbott’s medicines business; partnering to bring innovative health technologies to patients in more than 100 countries around the World.
Keith worked with a diverse portfolio of leading healthcare companies as Head of Lifesciences at Enterprise Ireland; an organisation that invests in innovation in companies from ranging from start-ups to multinationals. He has also held leadership roles at the Biomedical Diagnostics Institute and at the Broad Institute of MIT & Harvard, and sales and marketing roles at Harvard Bioscience and Stratagene.
Keith currently serves as Chair of the commercialisation advisory board of Royal College of Surgeons in Ireland and previously served as advisory board Chair for Knowledge Transfer Ireland, an initiative of the Government of Ireland to accelerate innovation, commercialisation and economic development.
SepTec is supported by an exceptional, multidisciplinary team of electrochemists, biologists, engineers and clinical key opinion leaders. Consequently, the groups research has had significant impact across an extensive range of scientific fields. For more information on the team’s research activities & achievements click the research button below!